This week, companies including MedRhythms, Allergan and Urotronic announced FDA clearances; Quest and Envision launched a prostate cancer test; and the FDA designated two recalls as class I.

This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.

Some defective devices with potential obstructions were mistakenly distributed to clients instead of being destroyed. 

Draeger has recalled two devices used to detect jaundice in newborns after users misinterpret display.